Navigation Links
ZIOPHARM Presents Unique Mechanism Data for Indibulin at AACR

LOS ANGELES--(BUSINESS WIRE)--Apr 16, 2007 - ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) presented preclinical data yesterday on indibulin (ZIO-301) at the American Association of Cancer Research (AACR) meeting in Los Angeles. These data demonstrate that indibulin has distinct biologic and molecular properties from other tubulin binding agents and strongly suggest a very different toxicity profile, particularly with regard to peripheral neuropathy. While indibulin binds to tubulin in general, it does not bind to neuronal specific tubulin and does not disrupt normal axonal microtubules in vitro, likely accounting for the difference with regard to neurotoxicity.

Indibulin is one of a class of cancer therapeutics that includes the taxanes (paclitaxel and docetaxel) and Vinca alkaloids, some of the most widely used anti-cancer agents in the world today. In spite of their effectiveness, all of the commercially available agents exhibit some degree of neurotoxicity that in many cases can be dose limiting.

Indibulin, like the taxanes and vinca alkaloids, interferes with the function of microtubules by binding to their building blocks, tubulin. However, the specific tubulin binding site for indibulin is different from that of taxanes and Vinca alkaloids. The observed lack of neurotoxicity in animals receiving indibulin treatment is thought to be related to this difference in binding site, and in particular to the observation that indibulin does not bind to neuronal-specific tubulin. Indibulin is active across a diverse range of human, mouse, and rat tumor cell lines in vitro and in human tumor xenografts, including glioblastoma and in drug-resistant tumor cell lines.

"We are very excited about indibulin's potential," commented Brian Schwartz, M.D., Chief Medical Officer at ZIOPHARM. "The fact that it is orally available and shows no signs of the neurotoxicity in preclinical models associated with other agents i n this class is particularly intriguing. If no neurotoxicity is seen in ongoing clinical trials, indibulin will clearly distinguish itself from other marketed agents in this class."

About ZIO-301

ZIO-301 (indibulin) is a novel synthetic anti-mitotic agent that binds to tubulin, destabilizes microtubulin polymerization, and arrests tumor cell growth at the G2/M phase. Microtubulins are well-established targets for anti-cancer drug development and tubulin-binding drugs such as taxanes and Vinca alkaloids are currently widely used to treat cancer. Indibulin is in a phase I dose-ranging and safety study in Europe. The Company expects to begin phase I/II trials in the U.S. soon.

About ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. For more information, visit

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risk s that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that the results of clinical trials may not support the Company's claims, and risks related to the Company's ability to protect its intellectual property and its reliance on third parties to develop its product candidates. The Company assumes no obligation to update these forward-looking statements, except as required by law.



ZIOPHARM Oncology, Inc.
Suzanne McKenna, 646-214-0703
Tina Posterli, 917-322-2565


Related medicine technology :

1. ZIOPHARM to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR
3. ZIOPHARM Presents Data on Orally Active ZIO-201 at AACR
4. ZIOPHARM Presents ZIO-201 Lymphoma Data at ISH
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
8. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
9. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
Post Your Comments:
(Date:11/30/2015)... 2015   Royal Philips  (NYSE: PHG ... Radiology Solutions, a fully integrated, consultative approach to ... data-driven practice management approaches that combine imaging systems, ... improve care delivery and reduce costs. Making its ... North America Annual Meeting (RSNA) in ...
(Date:11/30/2015)... -- global cell culture market is expected to ... by 2022 at a CAGR of 7.1% therein. --> ... 2013 value of US$6.1 bn to US$11.3 bn by 2022 at ... has announced the release of a new market research study, detailing ... Culture Market - Global Industry Analysis, Size, Share, Growth, Trends and ...
(Date:11/30/2015)... , Nov. 30, 2015   Royal Philips ... Implant, the industry,s first MRI guided user interface and ... of patients with MR Conditional implants, such as knee ... 2015 Radiological Society of North America Annual Meeting ... and supports diagnostic confidence of this growing patient population. ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 30, 2015 , ... Until now, the St. Louis Fetal Care Institute ... of Myelomeningocele Study) trial. One of these exclusion criteria was a BMI above 34.9. ... to 24.9 is considered normal, 25 - 29.9 is overweight and above 30 is ...
(Date:11/30/2015)... ... November 30, 2015 , ... Thermi™, a world ... announce that its ThermiRFR temperature controlled radiofrequency platform has received CE marking and ... platform which uses temperature as a clinical endpoint. The technology has been ...
(Date:11/30/2015)... ... November 30, 2015 , ... The world of hair transplants and restoration is ... These techniques and procedures have been in use for many years and are among ... Parsa Mohebi, M.D. has utilized many of these methods over the years, he also ...
(Date:11/30/2015)... ... November 30, 2015 , ... The presidential race normally ... styling. So why is it a national news story when Donald Trump makes disparaging ... M.D., because appearances count more than anyone wants to admit when it comes to ...
(Date:11/30/2015)... , ... November 30, 2015 , ... According to Los ... people to overeat are not necessarily caused by real hunger, but instead by ... needs food. He notes that, while many patients are aware that weight loss surgery ...
Breaking Medicine News(10 mins):